Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bortezomib + CPX-351 in Newly-Diagnosed TP53-mutated AML
NCT07008638Phase 2Recruiting
- Sponsor
- Masonic Cancer Center
- Start
- Jul 2025
- Primary completion
- Dec 2027
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of bortezomib in acute myeloid leukemia (AML), sponsored by Masonic Cancer Center. Started Jul 2025; status: recruiting.
02
Drugs
bortezomib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT07008638.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07008638.